{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T13:20:11Z","timestamp":1769606411496,"version":"3.49.0"},"reference-count":11,"publisher":"American Society of Hematology","issue":"10","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,5,24]]},"DOI":"10.1182\/bloodadvances.2021006949","type":"journal-article","created":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T22:13:10Z","timestamp":1643839990000},"page":"3068-3071","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":6,"title":["Antibody response to mRNA vaccination for COVID-19 in patients with AML receiving hypomethylating agents alone or with venetoclax"],"prefix":"10.1182","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4436-1310","authenticated-orcid":false,"given":"Anna","family":"Candoni","sequence":"first","affiliation":[{"name":"Division\u00a0of Hematology and Stem Cell Transplantation, ASUFC, Udine, Italy; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Callegari","sequence":"additional","affiliation":[{"name":"Division\u00a0of Hematology and Stem Cell Transplantation, ASUFC, Udine, Italy; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Elena","family":"Zannier","sequence":"additional","affiliation":[{"name":"Division\u00a0of Hematology and Stem Cell Transplantation, ASUFC, Udine, Italy; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renato","family":"Fanin","sequence":"additional","affiliation":[{"name":"Division\u00a0of Hematology and Stem Cell Transplantation, ASUFC, Udine, Italy; and"},{"name":"DAME, University of Udine, Udine, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2022,5,18]]},"reference":[{"issue":"15","key":"2022051815252461900_B1","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.1182\/bloodadvances.2020001920","article-title":"American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults","volume":"4","author":"Sekeres","year":"2020","journal-title":"Blood Adv."},{"issue":"7","key":"2022051815252461900_B2","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1038\/s41375-021-01218-0","article-title":"Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: mechanisms of resistance and novel HMA-based therapies","volume":"35","author":"Stomper","year":"2021","journal-title":"Leukemia."},{"issue":"1","key":"2022051815252461900_B3","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/s13045-021-01177-0","article-title":"COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA)","volume":"14","author":"Pagano","year":"2021","journal-title":"J Hematol Oncol."},{"issue":"10","key":"2022051815252461900_B4","doi-asserted-by":"crossref","first-page":"e737","DOI":"10.1016\/S2352-3026(20)30251-9","article-title":"Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study","volume":"7","author":"Passamonti","year":"2020","journal-title":"Lancet Haematol."},{"issue":"12","key":"2022051815252461900_B5","doi-asserted-by":"crossref","first-page":"2928","DOI":"10.1080\/10428194.2021.1948031","article-title":"Characteristics, clinical outcomes, and risk factors of SARS-COV-2 infection in adult acute myeloid leukemia patients: experience of the PETHEMA group","volume":"62","author":"Palanques-Pastor","year":"2021","journal-title":"Leuk Lymphoma."},{"issue":"5","key":"2022051815252461900_B6","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med."},{"issue":"3","key":"2022051815252461900_B7","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/bjh.17704","article-title":"COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies","volume":"195","author":"Passamonti","year":"2021","journal-title":"Br J Haematol."},{"key":"2022051815252461900_B8","first-page":"bloodadvances.2021006333","article-title":"Immunogenicity of COVID-19 vaccines in patients with hematological malignancy: a systematic review and meta-analysis","author":"Teh","journal-title":"Blood Adv."},{"issue":"8","key":"2022051815252461900_B9","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.ccell.2021.07.012","article-title":"Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies","volume":"39","author":"Greenberger","year":"2021","journal-title":"Cancer Cell."},{"issue":"6","key":"2022051815252461900_B10","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1158\/2643-3230.BCD-21-0139","article-title":"Disease- and therapy-specific impact on humoral immune responses to COVID-19 vaccination in hematologic malignancies","volume":"2","author":"Chung","year":"2021","journal-title":"Blood Cancer Discov."},{"issue":"8","key":"2022051815252461900_B11","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.ccell.2021.07.012","article-title":"Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies","volume":"39","author":"Greenberger","year":"2021","journal-title":"Cancer Cell."}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/10\/3068\/1897269\/advancesadv2021006949.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/10\/3068\/1897269\/advancesadv2021006949.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T15:25:45Z","timestamp":1652887545000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/6\/10\/3068\/483803\/Antibody-response-to-mRNA-vaccination-for-COVID-19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,18]]},"references-count":11,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,5,24]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2021006949","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,18]]}}}